SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLogistics Dev Regulatory News (LDG)

Share Price Information for Logistics Dev (LDG)

Share Price is delayed by 15 minutes
Get Live Data
13.75    0.00 (0.00%)
Bid:
13.50
Ask:
14.00
Spread: 0.50 (3.704%)
Market Cap: £56.90m
LDG Live PriceLast checked at - London Stock Exchange

Intraday Logistics Dev Share Chart

Form 8.3 - Mission Group PLC

21 May 2024 11:33

RNS Number : 3044P
DBAY Advisors Limited
21 May 2024
 

FORM 8.3

 

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

DBAY Advisors Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Pershing Nominees Ltd for Fixtaia Ltd and Logistics Development Group plc under the discretionary management of DBAY Advisors Limited.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Mission Group Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

20 May 2024

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

1p Ordinary

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

8,994,359

9.75

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

8,994,359

9.75

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

10p Ordinary Shares

Sale

172,475

23.68p

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

21 May 2024

Contact name:

Michael Haxby

Telephone number*:

01624 602132

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETBFLFLZELXBBL
Date   Source Headline
29th May 20267:00 amRNSPortfolio NAV Update
20th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
15th May 20262:20 pmRNSPortfolio company update - acquisition
15th May 20267:00 amRNSFinal Results for the year ended 31 December 2025
17th Mar 202611:00 amRNSPortfolio company update - acquisition
27th Feb 20267:00 amRNSPortfolio NAV Update
22nd Jan 20267:00 amRNSPortfolio Update - Related Party Transaction
28th Nov 20257:00 amRNSPortfolio NAV Update
6th Nov 20257:00 amRNSAppointment of Corporate Broker
25th Sep 20257:00 amRNSInterim Results for six months ended 30 June 2025
5th Sep 20253:53 pmRNSHolding(s) in Company
29th Aug 20257:00 amRNSPortfolio NAV Update
18th Jul 20254:09 pmRNSInvestment into platform to acquire APC
25th Jun 202512:55 pmRNSResult of AGM
5th Jun 20257:00 amRNSUpdate re Directors’ & Concert Party shareholdings
30th May 20257:00 amRNSPortfolio NAV Update
28th May 20257:00 amRNSPosting of Annual Report and Notice of AGM
22nd May 20257:00 amRNSFinal Results for the 13 Months to 31 Dec 2024
24th Apr 20257:00 amRNSResults of Tender Offer
22nd Apr 202512:28 pmRNSResults of General Meeting
28th Mar 20257:00 amRNSProposed Tender Offer, Circular, & GM Notice
17th Mar 20257:00 amRNSPortfolio NAV and Distribution Update
10th Jan 202511:59 amRNSForm 8 (OPD) - Alliance Pharma PLC
10th Jan 20257:29 amRNSAlliance Pharma Investment - Update
10th Jan 20257:00 amRNSRecommended Acquisition of Alliance Pharma plc
24th Dec 202410:57 amRNSRedemption of investment; distribution update
29th Nov 20241:00 pmRNSBoard Changes, Change of Accounting Reference Date
16th Oct 20241:41 pmRNSResult of Requisitioned General Meeting
23rd Sep 20247:00 amRNSCircular Publication, Notice of Requisitioned GM
4th Sep 20243:29 pmRNSResults of General Meeting
4th Sep 20247:00 amRNSGeneral Meeting Requisition Notice
23rd Aug 20247:00 amRNSInterim Results for six months ended 31 May 2024
13th Aug 20247:00 amRNSCircular, Rule 9 Waiver & Notice of GM
5th Aug 202411:56 amRNSHolding(s) in Company
11th Jul 202411:02 amRNSHolding(s) in Company
11th Jul 20249:27 amRNSForm 8.3 - Mission Group PLC
12th Jun 20245:57 pmRNSNotification of Major Holdings
31st May 202411:00 amRNSForm 8.3 - Mission Group plc
30th May 20241:14 pmRNSForm 8.3 - Mission Group plc
30th May 202412:00 pmRNSNotification of Major Holdings
29th May 202410:16 amRNSForm 8.3 - Mission Group PLC
28th May 20241:09 pmRNSHolding(s) in Company
28th May 202410:52 amRNSForm 8.3 - Mission Group Plc
28th May 202410:34 amRNSForm 8.3
24th May 20242:44 pmRNSHolding(s) in Company
24th May 20248:56 amRNSHolding(s) in Company
23rd May 202411:21 amRNSForm 8.3 - Mission Group PLC
23rd May 20249:00 amRNSHolding(s) in Company
22nd May 202410:36 amRNSForm 8.3
21st May 202411:33 amRNSForm 8.3 - Mission Group PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.